Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: A nested case-control study

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 603-609

  Le Ray, Isabelle ^a,b   Dell'Aniello, Sophie ^c   Bonnetain, Franck ^a   Azoulay, Laurent ^c,d   Suissa, Samy ^c,d  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Estrogen receptor; Local hormonal therapy; Recurrence rate; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; PLACEBO; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; CREAM; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RECURRENCE RISK; TABLET; TREATMENT DURATION; UNITED KINGDOM;

ADMINISTRATION, INTRAVAGINAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; RETROSPECTIVE STUDIES; TAMOXIFEN; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINAL DISEASES;

EID: 84866542410     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2198-y     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
2. Perez EA (2007) Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 18(Suppl 8):26-35
3. Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72:829-842 (Pubitemid 47410069)
4. Chin SN, Trinkaus M, Simmons C, Flynn C, Dranitsaris G, Bolivar R, Clemons M (2009) Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 9:108-117
5. Mok K, Juraskova I, Friedlander M (2008) The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. Breast 17:436-440
6. Baumgart J, Nilsson K, Stavreus-Evers A, Kask K, Villman K, Lindman H, Kallak T, Sundström-Poromaa I (2011) Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 204(26):e1-7
7. Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 14(Suppl 1):S20-40
8. Kendall A (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584-587
9. Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097-1099 (Pubitemid 27437871)
10. García Rodríguez LA, Pérez Gutthann S (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45:419-425 (Pubitemid 28227341)
11. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 302:766-768
12. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research; the use of general practice databases. J Public Health Med 21:299-304 (Pubitemid 29446069)
13. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23:686-689 (Pubitemid 36539051)
14. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49:591-596 (Pubitemid 30326559)
15. Suissa S (2005) Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Dans Strom B (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 811-829
16. Essebag V, Platt RW, Abrahamowicz M, Pilote L (2005) Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 5:5
17. Essebag V, Genest J Jr, Suissa S, Pilote L (2003) The nested case-control study in cardiology. Am Heart J 146:581-590 (Pubitemid 37281701)
18. Azoulay L, Dell'Aniello S, Huiart L, du Fort GG, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126: 695-703
19. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC (1988) Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812-815 (Pubitemid 18061868)
20. Polin SA, Ascher SM (2008) The effect of tamoxifen on the genital tract. Cancer Imaging 8:135-145 (Pubitemid 351936271)
21. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH (1999) Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17:1488-1492 (Pubitemid 29220856)
22. Mourits MJ, Böckermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, Sluiter WJ, Willemse PH (2002) Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 86:1546-1550 (Pubitemid 34628106)
23. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97:855-866 (Pubitemid 32406196)
24. Dew JE, Wren BG, Eden JA (2003) A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6:45-52 (Pubitemid 36398872)
25. Dew JE, Wren BG, Eden JA (2002) Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 5:151-155 (Pubitemid 34548215)
26. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, Ponzone R, Sismondi P (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 26:404-412
27. Cuzick J, Sestak I, Cella D, Fallowfield L et al (2008) Treatmentemergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143-1148